Preventing kidney injury after heart surgery with a proton pump inhibitor
Official title: Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial): A Prospective Randomized Controlled Trial
Run by The University of Texas Health Science Center, Houston · NCT06706258 · Data updated 2026-11-12
This study is testing if giving the heart surgery patients a medication called pantoprazole can help prevent kidney injuries after their surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | January 24, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | July 1, 2027 |
| Registry record updated | May 14, 2025 |
| Trial ID | NCT06706258 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 90 scheduled for elective cardiac surgery with a moderate to high risk of developing AKI.
✕Probably not a fit
Patients with severe preoperative kidney impairment, those requiring dialysis, or those undergoing emergency surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates whether administering the proton pump inhibitor pantoprazole perioperatively can reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery. The study will randomly assign 400 adult patients to receive either pantoprazole or famotidine for three days following surgery. By examining molecular pathways involved in kidney protection, the trial aims to determine if pantoprazole can mitigate the risk of AKI and related adverse kidney events. The outcomes will be assessed at 30 days post-surgery, focusing on urine biomarkers and clinical events.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the occurrence of acute kidney injury in patients undergoing cardiac surgery, leading to better postoperative outcomes.
How similar studies have gone: While the use of proton pump inhibitors for kidney protection is being explored, this specific approach is novel and has not been extensively tested in the context of cardiac surgery.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age 18-90). * Scheduled for elective cardiac surgery with cardiopulmonary bypass. * Moderate to high risk of developing AKI (Cleveland risk score equal to or higher than 3. Exclusion Criteria: * Patients with preoperative eGFR\<30 ml/min/1.73 m2 * Dialysis dependence * Emergency surgery * Pregnancy. * Nursing patient * Patients with interstitial nephritis * PPIs hypersensitivity * Liver disease * Vitamin B12 deficiency.
Where it's running
-
Memorial Hermann Texas Medical Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Yafen Liang, MD — The University of Texas Health Science Center, Houston
- Study coordinator: Yafen Liang, MD
- Email: yafen.liang@uth.tmc.edu
- Phone: 713-500-6226
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery
This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Biomarkers to predict CSA-AKI risk before heart surgery
This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.
-
Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter
This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.
-
Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI
This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.
-
Restarting RAS inhibitors after AKI: a quick test in hospitalized adults
This pilot study tests whether restarting renin-angiotensin system inhibitors early after acute kidney injury is feasible and safe in hospitalized adults already using these medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.